Temafloxacin
Overview[edit]
Temafloxacin is a fluoroquinolone antibiotic that was developed for the treatment of bacterial infections. It was marketed under the brand name Omniflox. Temafloxacin was primarily used to treat respiratory tract infections, urinary tract infections, and skin infections.
Chemical Structure[edit]
Temafloxacin is a synthetic antibiotic belonging to the fluoroquinolone class. The chemical structure of temafloxacin includes a fluorine atom at the C-6 position and a piperazine moiety at the C-7 position, which are characteristic features of fluoroquinolones.
Mechanism of Action[edit]
Temafloxacin works by inhibiting bacterial DNA gyrase and topoisomerase IV, enzymes that are essential for bacterial DNA replication and transcription. By interfering with these processes, temafloxacin effectively halts bacterial cell division and leads to cell death.
Clinical Use[edit]
Temafloxacin was indicated for the treatment of various bacterial infections, including:
- Community-acquired pneumonia
- Acute bacterial exacerbation of chronic bronchitis
- Urinary tract infections
- Skin and soft tissue infections
Withdrawal from Market[edit]
In 1992, temafloxacin was withdrawn from the market due to serious adverse effects, including hemolytic anemia, thrombocytopenia, and renal failure. These adverse reactions were severe and led to the decision to discontinue its use.
Adverse Effects[edit]
The adverse effects associated with temafloxacin included:
